Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What is cost-effectiveness analysis?

D B Evans1

  • 1Centre for Clinical Epidemiology and Biostatistics, Faculty of Medicine, University of Newcastle, Shortland, NSW.

The Medical Journal of Australia
|August 6, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2016
Same author

Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2016
Same author

Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO).

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2016
Same author

Patency rates of portal vein/superior mesenteric vein reconstruction after pancreatectomy for pancreatic cancer.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2014
Same author

What are the priorities for prevention and control of non-communicable diseases and injuries in sub-Saharan Africa and South East Asia?

BMJ (Clinical research ed.)·2012
Same author

Infectious complications of transplantation surgery.

Proceedings of the Royal Society of Medicine·2010
Same journal

Responding to the Revised First Nations Health and Cultural Safety Accreditation Standards in Australian Primary Medical Education: Institutional Principles and Qualities for Meaningful Progress.

The Medical journal of Australia·2026
Same journal

Multimorbidity Clusters Among People Aged 65 Years and Over in Australia: A Nationwide Cross-Sectional Data Linkage Study.

The Medical journal of Australia·2026
Same journal

Reducing Nitrous Oxide Emissions Across the Melbourne Biomedical Precinct.

The Medical journal of Australia·2026
Same journal

Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population.

The Medical journal of Australia·2026
Same journal

Striving for Racial Equity in Oral Cancer Research: A Case Study.

The Medical journal of Australia·2026
Same journal

Progressing Cross-Sector Collaboration for People With Eating Disorders and Higher Weight: Priority Actions From an Expert Roundtable Using a Modified Nominal Group Technique.

The Medical journal of Australia·2026
See all related articles

Cost-effectiveness analysis (CEA) evaluates the economic efficiency of hypertension treatments. CEA guides resource allocation decisions by comparing intervention costs to health outcomes, despite some challenges.

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Clinical Decision Making

Background:

  • Hypertension treatment requires careful economic evaluation.
  • Pharmacological interventions necessitate assessment of economic efficiency.
  • Resource allocation in healthcare is a critical concern.

Purpose of the Study:

  • To illustrate the role of cost-effectiveness analysis (CEA) in assessing pharmacological interventions for hypertension.
  • To discuss the importance of economic efficiency in healthcare decisions.
  • To outline the key issues in conducting CEA.

Main Methods:

  • Focus on measuring benefits using intermediate and final outcome indicators.
  • Introduction of the concept of marginal cost-effectiveness analysis.

Related Experiment Videos

  • Examination of economic efficiency in the context of mild-to-moderate hypertension treatment.

    • Main Results:

    • CEA provides a framework for evaluating the economic efficiency of health interventions.
    • The choice of outcome indicators (intermediate vs. final) impacts CEA results.
    • Marginal CEA offers insights into incremental resource allocation decisions.

    Conclusions:

    • Cost-effectiveness analysis is a valuable tool for guiding healthcare resource allocation.
    • Despite complexities, CEA aids in making informed decisions about pharmacological treatments.
    • Economic evaluation is essential for optimizing healthcare spending and outcomes.